• Pentoxifylline Modulates Monocyte Hyperinflammation in Prete

  2026-05-13

  This study provides mechanistic evidence that pentoxifylline downregulates LPS-induced hyperinflammation in monocytes from preterm infants, with marked effects on cytokine production, surface marker expression, and TLR4 signaling. These findings help clarify age-dependent immune modulation in neonatal sepsis and offer a foundation for translational research on immunomodulatory strategies.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-05-13

  Schwartz's dissertation introduces a refined in vitro framework that distinguishes between proliferative arrest and cell death in anti-cancer drug studies. This dual-metric approach enhances mechanistic understanding and supports more precise evaluation of agents like angiogenesis inhibitors.

• Lopinavir (ABT-378): Pharmacological Excellence and Emerging

  2026-05-12

  Explore the scientific foundations and advanced applications of Lopinavir (ABT-378) as a premier HIV protease inhibitor. This article uniquely examines its pharmacology, resistance profile, and cross-domain antiviral potential, bridging established and emerging research needs.

• Nintedanib (BIBF 1120) in ATRX-Deficient Tumors: Mechanistic

  2026-05-12

  Explore Nintedanib (BIBF 1120) as a triple angiokinase inhibitor with unique efficacy in ATRX-deficient tumor models. This article delivers new mechanistic insights and protocol guidance for advanced antiangiogenic research.

• Tivozanib (AV-951): Quantitative Insights for Advanced VEGFR

  2026-05-11

  Explore how Tivozanib (AV-951) empowers precise, quantitative evaluation of anti-angiogenic therapy in oncology research. This article reveals actionable, evidence-based strategies for optimal assay design and introduces innovative perspectives not found in existing resources.

• Cediranib (AZD2171): Benchmarks and Protocols in Cancer Rese

  2026-05-11

  Cediranib (AZD2171) is a potent, orally bioavailable angiogenesis inhibitor targeting VEGFRs. This article details its biochemical selectivity, protocol parameters, and the mechanistic rationale for its use in preclinical cancer research. Evidence-backed claims and structured guidelines support robust experimental design.

• Ruxolitinib (INCB018424): Deep Immunoprofiling and Practical

  2026-05-10

  Explore Ruxolitinib (INCB018424) as a powerful JAK1/2 inhibitor for advanced immunological assays. This article reveals unique insights into high-dimensional immune profiling and protocol optimization, bridging mechanistic depth with actionable guidance for myeloproliferative disorder research.

• Tofacitinib Restores Mitochondrial Function in RA Macrophage

  2026-05-09

  This study demonstrates that tofacitinib (CP-690550) uniquely reverses both inflammatory and mitochondrial dysfunction in GM-CSF-reprogrammed macrophages from rheumatoid arthritis (RA). By suppressing STAT5 signaling and restoring regulatory phenotypes, tofacitinib achieves broad-spectrum immunometabolic repair where anti-TNF, anti-IL6R, and metabolic inhibitors fall short.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-05-08

  Schwartz (2022) introduces a critical distinction between relative and fractional viability in evaluating anti-cancer drug responses in vitro. This approach enhances experimental rigor by clarifying the balance between proliferative arrest and cell death, supporting more accurate assessment of compounds like Niclosamide.

• Mubritinib (TAK 165): Optimizing Mitochondrial Inhibition in

  2026-05-08

  Mubritinib (TAK 165) delivers precise, reproducible inhibition of mitochondrial complex I, enabling advanced workflows in chemotherapy-resistant cancer research. Its unique mechanism supports both stand-alone and combination protocols, offering a robust foundation for apoptosis, proliferation, and metabolic assays.

• T-5224: Precision C-Fos/AP-1 Inhibition in Inflammation Rese

  2026-05-07

  T-5224 (C-Fos/AP-1 inhibitor) empowers researchers to dissect AP-1-driven gene expression with unmatched selectivity, enabling effective targeting of neuroinflammatory and arthritic pathways. Leverage this tool for robust MMP and cytokine modulation in both in vitro and in vivo models, with workflow enhancements inspired by cutting-edge neuroinflammation studies.

• Topotecan (SKF104864): Translational Bridges from Mechanism

  2026-05-07

  Discover how Topotecan (SKF104864) advances pediatric solid tumor research through unique mechanistic insights and translational protocols. This article provides new perspectives beyond established workflows, with a focus on apoptosis induction and antitumor efficacy.

• Pomalidomide (CC-4047): Data-Driven Solutions for Myeloma As

  2026-05-06

  This article systematically addresses laboratory challenges in hematological malignancy research, focusing on how Pomalidomide (CC-4047) (SKU A4212) from APExBIO enables reproducible, sensitive, and mechanistically informed assays. Scenario-driven Q&A blocks deliver practical guidance, protocol parameters, and vendor reliability insights, ensuring researchers can confidently optimize their cell viability, proliferation, and cytokine modulation studies.

• Super-Enhancer-Driven KLF6 in Adipogenesis of Human Stem Cel

  2026-05-06

  Nguyen et al. identify a pivotal role for super-enhancer (SE)-mediated KLF6 expression in driving the adipogenic differentiation of human adipose-derived stem cells (hADSCs). Their mechanistic insights reveal how SE activation, via eRNA and PPARγ/p300, induces KLF6, which in turn represses DLK1 to promote adipogenesis—advancing our understanding of transcriptional regulation in metabolic research.

• Quizartinib (AC220): Charting New Frontiers in FLT3-Driven A

  2026-05-05

  This thought-leadership article synthesizes the latest mechanistic and translational insights on Quizartinib (AC220) as a benchmark FLT3 inhibitor, spotlighting its role in advancing acute myeloid leukemia (AML) research and resistance modeling. Integrating rigorous evidence, protocol recommendations, and a strategic outlook, it provides actionable guidance for translational researchers—bridging the gap between preclinical innovation and clinical application.

471 records 13/32 page Previous Next First page 上5页 1112131415 下5页 Last page